Document Detail


Contradictory effects of β1- and α1- aderenergic receptor blockers on cardio-ankle vascular stiffness index (CAVI)--CAVI independent of blood pressure.
MedLine Citation:
PMID:  21071883     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
AIM: The cardio-ankle vascular stiffness index (CAVI) is a new parameter that reflects the stiffness of the aorta, femoral artery and tibial artery as a whole. One of its conspicuous features is that CAVI is independent of blood pressure at measuring time, theoretically. But, it has not been experimentally proved yet. For confirmation, pharmacological studies were performed comparing with brachial-ankle pulse wave velocity (baPWV).
METHODS: Used drugs were a β1-adrenoceptor blocker, metoprorol and an α1- adrenoceptor blocker doxazosin. Both were administered to 12 healthy volunteer men. CAVI and baPWV were measured every one hour for 6 hours using VaSera.
RESULTS: When metoprolol (80 mg) was administered to 12 healthy volunteer men, systolic blood pressure decreased from 131.4 ± 4.5 to 118.3 ± 4.1 mmHg (mean ± SE) (p < 0.05) at the 3rd hour, and diastolic blood pressure decreased from 85.3 ± 4.0 to 75.3 ± 3.0 mm Hg (p < 0.05). baP-WV decreased from 13.93 ± 0.46 to 12.46 ± 0.49 m/sec (p < 0.05), significantly, but CAVI did not change (8.16 ± 0.29 to 8.24 ± 0.27) (p = 0.449). ΔbaPWV at each time was significantly correlated with both Δsystolic and Δdiastolic blood pressures, but ΔCAVI was not correlated with either Δblood pressure. When doxazosin (4 mg) was administered to the same men, systolic blood pressure decreased from 130.2 ± 4.6 to 117.2 ± 4.8 mmHg (p < 0.05) at the 3rd hour. Diastolic blood pressure also decreased from 85.1 ± 4.1 to 74.2 ± 3.9 mmHg (p < 0.05). baPWV decreased from 13.98 ± 0.68 to 12.25 ± 0.53 m/sec (p < 0.05), significantly. CAVI also decreased from 8.15 ± 0.28 to 7.18 ± 0.37 (p < 0.05), significantly.
CONCLUSION: These results suggested that CAVI was not affected by blood pressure at the measuring time directly, but affected by the changes of contractility of smooth muscle cells.
Authors:
Kohji Shirai; Mingling Song; Jun Suzuki; Takumi Kurosu; Tomokazu Oyama; Daiji Nagayama; Yoh Miyashita; Shigeo Yamamura; Mao Takahashi
Related Documents :
9246863 - Theoretical analysis of non-invasive oscillometric maximum amplitude algorithm for esti...
18595353 - Separation of the reservoir and wave pressure and velocity from measurements at an arbi...
9039243 - Secondary failure of nasal intermittent positive pressure ventilation using the monnal ...
Publication Detail:
Type:  Journal Article     Date:  2010-11-06
Journal Detail:
Title:  Journal of atherosclerosis and thrombosis     Volume:  18     ISSN:  1880-3873     ISO Abbreviation:  J. Atheroscler. Thromb.     Publication Date:  2011  
Date Detail:
Created Date:  2011-02-01     Completed Date:  2011-05-31     Revised Date:  2011-10-05    
Medline Journal Info:
Nlm Unique ID:  9506298     Medline TA:  J Atheroscler Thromb     Country:  Japan    
Other Details:
Languages:  eng     Pagination:  49-55     Citation Subset:  IM    
Affiliation:
Internal Medicine, Sakura Hospital, School of Medicine, Toho University, Chiba, Japan. kshirai@kb3.so-net.ne.jp
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenergic alpha-Antagonists / pharmacology*
Adrenergic beta-Antagonists / pharmacology*
Adult
Ankle Brachial Index*
Blood Pressure / drug effects*
Humans
Male
Middle Aged
Receptors, Adrenergic, alpha-1 / drug effects*
Receptors, Adrenergic, beta-1 / drug effects*
Chemical
Reg. No./Substance:
0/Adrenergic alpha-Antagonists; 0/Adrenergic beta-Antagonists; 0/Receptors, Adrenergic, alpha-1; 0/Receptors, Adrenergic, beta-1
Comments/Corrections
Comment In:
J Atheroscler Thromb. 2011 Aug 24;18(8):720; author reply 721-2   [PMID:  21532238 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Relationship between peripheral arterial disease and incident disability among elderly Japanese: the...
Next Document:  An overview of genetic polymorphisms and pancreatic cancer risk in molecular epidemiologic studies.